{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:12:13Z","timestamp":1783041133180,"version":"3.54.6"},"reference-count":62,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Multiple myeloma (MM) is a malignancy of clonal plasma cells accounting for approximately 10% of haematological malignancies. MM mainly affects older patients, more often males and is more frequently seen in African Americans. The most frequent manifestations of MM are anaemia, osteolytic bone lesions, kidney failure and hypercalcemia. The anaemia develops secondary to suppression of erythropoiesis by cytokine networks, similarly to the mechanism of anaemia of chronic disease. The concomitant presence of kidney failure, especially chronic kidney disease (CKD) and MM per se, leading to anaemia of chronic disease (ACD) in combination, provoked us to pose the question about their reciprocal dependence and relationship with specific biomarkers; namely, soluble transferrin receptor (sTfR), growth differentiation factor 15 (GDF15), hepcidin 25 and zonulin. One or more of these are new biomarkers of ferric management may be utilized in the near future as prognostic predictors for patients with MM and kidney failure.<\/jats:p>","DOI":"10.3390\/jcm8111828","type":"journal-article","created":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T12:30:50Z","timestamp":1572611450000},"page":"1828","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["New Biomarkers of Ferric Management in Multiple Myeloma and Kidney Disease-Associated Anemia"],"prefix":"10.3390","volume":"8","author":[{"given":"Ma\u0142gorzata","family":"Banaszkiewicz","sequence":"first","affiliation":[{"name":"Departament of Nephrology, Jagiellonian University Medical College, Kopernika 15-15c, 31-501 Cracow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Ma\u0142yszko","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Dialysis and Internal Medicine, Warsaw Medical University, Banacha 1a, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Vesole","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center, Hackensack University Medical Center, 92 2nd St, Hackensack, NJ 07601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Woziwodzka","sequence":"additional","affiliation":[{"name":"Departament of Nephrology, Jagiellonian University Medical College, Kopernika 15-15c, 31-501 Cracow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Jurczyszyn","sequence":"additional","affiliation":[{"name":"Departament of Hematology, Jagiellonian University Medical College, Kopernika 17, 30-501 Cracow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"\u017b\u00f3rawski","sequence":"additional","affiliation":[{"name":"Departament of Clinical Medicine, Medical University, Szpitalna 37, 15-254 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Krzanowski","sequence":"additional","affiliation":[{"name":"Departament of Nephrology, Jagiellonian University Medical College, Kopernika 15-15c, 31-501 Cracow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Ma\u0142yszko","sequence":"additional","affiliation":[{"name":"Departament of Nephrology, Medical University, \u017burawia 14, 15-540 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Batko","sequence":"additional","affiliation":[{"name":"Departament of Nephrology, Jagiellonian University Medical College, Kopernika 15-15c, 31-501 Cracow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Ku\u017aniewski","sequence":"additional","affiliation":[{"name":"Departament of Nephrology, Jagiellonian University Medical College, Kopernika 15-15c, 31-501 Cracow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8120-8994","authenticated-orcid":false,"given":"Katarzyna","family":"Krzanowska","sequence":"additional","affiliation":[{"name":"Departament of Nephrology, Jagiellonian University Medical College, Kopernika 15-15c, 31-501 Cracow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,11,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"Jurczyszyn, A., and Skotnicki, A. (2010). Multiple Myeloma. Comprehensive Diagnostics and Therapy, Wydawnictwo Medyczne. [1st ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 Patients With Newly Diagnosed Multiple Myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1182\/blood.V128.22.4794.4794","article-title":"Evaluation of Cardiovascular Comorbidities Among Patients with Multiple Myeloma in the United States","volume":"128","author":"Lenihan","year":"2016","journal-title":"Blood"},{"key":"ref_5","unstructured":"(2019, September 29). National Registry of Malignancies: Multiple Myeloma and malignancies of plasma cells (C90). Available online: http:\/\/onkologia.org.pl\/szpiczak-mnogi-nowotwory-komorek-plazmatycznych-c90\/."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1615\/CritRevOncog.2013007934","article-title":"Iron in multiple myeloma","volume":"18","author":"VanderWall","year":"2013","journal-title":"Crit. Rev. Oncog."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/ndt\/gfp488","article-title":"Presentation and survival of patients with severe acute kidney injury and multiple myeloma: A 20-year experience from a single centre","volume":"25","author":"Haynes","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"429","DOI":"10.5455\/medarh.2016.70.429-432","article-title":"Dilemma: Correlation Between Serum Level of Hepcidin and IL-6 in Anemic Myeloma Patients","volume":"70","author":"IbricevicBalic","year":"2016","journal-title":"Med. Arch."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.3324\/haematol.2015.124511","article-title":"Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease","volume":"100","author":"Westhrin","year":"2015","journal-title":"Haematologica"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1182\/blood-2013-08-524025","article-title":"Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells","volume":"123","author":"Tanno","year":"2014","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1532\/LH96.05030","article-title":"Evaluation of Hypochromic Erythrocytes in Combination with sT fR-F Index for Predicting Response to r-HuEPO in Anemic Patients with Multiple Myeloma","volume":"12","author":"Katodritou","year":"2006","journal-title":"Lab. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1152\/physrev.00003.2008","article-title":"Zonulin and Its Regulation of Intestinal Barrier Function: The Biological Door to Inflammation, Autoimmunity, and Cancer","volume":"91","author":"Fasano","year":"2011","journal-title":"Physiol. Rev."},{"key":"ref_13","first-page":"233","article-title":"Anemia in multiple myeloma","volume":"2","author":"Ludwig","year":"2004","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1182\/blood-2010-03-274571","article-title":"In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2","volume":"116","author":"Maes","year":"2010","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF02983379","article-title":"Recent Advances in Understanding the Pathogenesis of Anemia in Multiple Myeloma","volume":"78","author":"Silvestris","year":"2003","journal-title":"Int. J. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood-2011-04-347484","article-title":"Multiple myeloma\u2013related deregulation of bone marrow\u2013derived CD34+ hematopoietic stem and progenitor cells","volume":"120","author":"Bruns","year":"2012","journal-title":"Blood"},{"key":"ref_17","unstructured":"Jurczyszyn, A., and Skotnicki, A. (2011). Multiple Myeloma. Selected Issues, Wydawnictwo Medyczne. [1st ed.]."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1600-0609.2006.00739.x","article-title":"Evaluation of anaemia in patients with multiple myeloma and lymphoma: Findings of the European CANCER ANAEMIA SURVEY","volume":"77","author":"Ludwig","year":"2006","journal-title":"Eur. J. Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.beha.2005.01.013","article-title":"Renal, hematologic and infectious complications in multiple myeloma","volume":"18","year":"2005","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.3816\/CLM.2003.s.005","article-title":"The implications of anemia in multiple myeloma","volume":"4","author":"Mittelman","year":"2003","journal-title":"Clin. Lymphoma"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s10456-013-9369-2","article-title":"Erythropoietin is involved in the angiogenic potential of bone marrow macrophages in multiple myeloma","volume":"16","author":"Binetti","year":"2013","journal-title":"Angiogenesis"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2018-99-110805","article-title":"The Medalist Trial: Results of a phase 3, randomized, double-blind, placebo-controlled study of luspatercept to treat anemia in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts (RS) who require red","volume":"132","author":"Fenaux","year":"2018","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/MNH.0000000000000433","article-title":"Activin receptor ligand traps in chronic kidney disease","volume":"27","author":"Jelkmann","year":"2018","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"335","DOI":"10.4103\/1319-2442.178557","article-title":"Outcome of patients with multiple myeloma and renal failure on novel regimens","volume":"27","author":"Soleymanian","year":"2016","journal-title":"Saudi J. Kidney Dis. Transplant."},{"key":"ref_26","first-page":"722","article-title":"Clinical Research about Risk Factors and Reversible Predictors in Renal Impairment due to Multiple Myeloma","volume":"23","author":"Liu","year":"2015","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref_27","first-page":"1913","article-title":"Hepcidin","volume":"57","author":"Ganz","year":"2016","journal-title":"Rinsho Ketsueki"},{"key":"ref_28","first-page":"1767","article-title":"Hepcidin\u2013Minireview","volume":"7","author":"Ganesh","year":"2013","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1158\/1078-0432.CCR-07-4153","article-title":"Involvement of Hepcidin in the Anemia of Multiple Myeloma","volume":"14","author":"Sharma","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.7754\/Clin.Lab.2017.160637","article-title":"Serum Hepcidin Levels in Multiple Myeloma","volume":"63","author":"Victor","year":"2017","journal-title":"Clin. Lab."},{"key":"ref_31","first-page":"403","article-title":"Peripheral blood monocyte hepcidin in patients with multiple myeloma is associated with anemia of chronic disease","volume":"21","author":"Han","year":"2013","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref_32","first-page":"1316","article-title":"C\/EBP\u03b1 in multiple myeloma patients may lead to increased hepcidin","volume":"22","author":"Han","year":"2014","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s12185-014-1626-7","article-title":"Hepcidin and GDF15 in anemia of multiple myeloma","volume":"100","author":"Mei","year":"2014","journal-title":"Int. J. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/ajh.21448","article-title":"Sequential evaluation of serum hepcidin in anemic myeloma patients: Study of correlations with myeloma treatment, disease variables, and anemia response","volume":"84","author":"Katodritou","year":"2009","journal-title":"Am. J. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3892\/etm.2012.663","article-title":"Serum prohepcidin levels are potential prognostic markers in patients with multiple myeloma","volume":"4","author":"Haraguchi","year":"2012","journal-title":"Exp. Ther. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1159\/000368512","article-title":"Iron Status and Inflammation in Early Stages of Chronic Kidney Disease","volume":"40","author":"Tobolczyk","year":"2015","journal-title":"Kidney Blood Press. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1182\/blood-2008-02-139915","article-title":"Immunoassay for human serum hepcidin","volume":"112","author":"Ganz","year":"2008","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1681\/ASN.2016080919","article-title":"Growth Differentiation Factor\u201315 and Risk of CKD Progression","volume":"28","author":"Nair","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"946","DOI":"10.5966\/sctm.2013-0055","article-title":"Concise review: Growth differentiation factor 15 in pathology: A clinical role?","volume":"2","author":"Corre","year":"2013","journal-title":"Stem Cells Transl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1182\/blood-2017-12-819904","article-title":"Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis","volume":"131","author":"Kastritis","year":"2018","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1158\/0008-5472.CAN-11-0188","article-title":"Bioactivity and Prognostic Significance of Growth Differentiation Factor GDF15 Secreted by Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma","volume":"72","author":"Corre","year":"2012","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1258\/0004563021902152","article-title":"Serum transferrin receptor assays and their application","volume":"39","author":"Worwood","year":"2002","journal-title":"Ann. Clin. Biochem."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Petzer, V., Theurl, I., and Weiss, G. (2018). Established and Emerging Concepts to Treat Imbalances of Iron Homeostasis in Inflammatory Diseases. Pharmaceuticals (Basel), 11.","DOI":"10.3390\/ph11040135"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3109\/10408363.2010.550461","article-title":"Biological and clinical aspects of soluble transferrin receptor","volume":"47","author":"Speeckaert","year":"2010","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000354835","article-title":"Serum Growth Differentiation Factor 15 Levels in Newly Diagnosed Multiple Myeloma Patients","volume":"131","author":"Tarkun","year":"2014","journal-title":"Acta Haematol."},{"key":"ref_46","first-page":"1973","article-title":"Testing of a Novel Cancer Metastatic Multiplex Panel for the Detection of Bone-metastatic Disease\u2014A Pilot Study","volume":"36","author":"Windrichova","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_47","first-page":"270","article-title":"Expression of serum GDF15 and its clinical significance in multiple myeloma patients","volume":"39","author":"Zhao","year":"2014","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s11255-016-1278-z","article-title":"GDF-15, iron, and inflammation in early chronic kidney disease among elderly patients","volume":"48","author":"Lukaszyk","year":"2016","journal-title":"Int. Urol. Nephrol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000039750","article-title":"Clinical Usefulness of Combined Measurements of Serum Soluble Transferrin Receptor Levels and Serum Interleukin-18 Levels at Determination of Serum KL-6 Levels in Haematologic Malignancies","volume":"104","author":"Takubo","year":"2000","journal-title":"Acta Haematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e13939","DOI":"10.14814\/phy2.13939","article-title":"Apelinergic system in the kidney: Implications for diabetic kidney disease","volume":"6","author":"Kalea","year":"2018","journal-title":"Physiol. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"333","DOI":"10.17305\/bjbms.2017.1972","article-title":"Soluble transferrin receptor as a marker of erythropoiesis in patients undergoing high-flux hemodialysis","volume":"17","author":"Yin","year":"2017","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"ref_52","first-page":"53","article-title":"Inadequate erythropoietin production (epo) in patients with multiple myeloma","volume":"25","author":"Kostova","year":"2004","journal-title":"Prilozi"},{"key":"ref_53","first-page":"848","article-title":"Stages of chronic kidney disease and soluble Transferrin Receptor (sTfR), Ferritin, ratio","volume":"67","author":"Alam","year":"2017","journal-title":"J. Pak. Med. Assoc."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"16799","DOI":"10.1073\/pnas.0906773106","article-title":"Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2","volume":"106","author":"Tripathi","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1016\/j.transproceed.2014.09.018","article-title":"Zonulin, Iron Status, and Anemia in Kidney Transplant Recipients: Are They Related?","volume":"46","author":"Malyszko","year":"2014","journal-title":"Transplant. Proc."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.peptides.2009.03.017","article-title":"Zonulin is not increased in the cardiac and esophageal mucosa of patients with gastroesophageal reflux disease","volume":"30","author":"Wex","year":"2009","journal-title":"Peptides"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12016-011-8291-x","article-title":"Leaky Gut and Autoimmune Diseases","volume":"42","author":"Fasano","year":"2012","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4274\/jcrpe.3682","article-title":"The Relationship between Serum Zonulin Level and Clinical and Laboratory Parameters of Childhood Obesity","volume":"9","author":"Acar","year":"2017","journal-title":"J. Clin. Res. Pediatr. Endocrinol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Ohlsson, B., Orho-Melander, M., and Nilsson, P. (2017). Higher Levels of Serum Zonulin May Rather Be Associated with Increased Risk of Obesity and Hyperlipidemia, Than with Gastrointestinal Symptoms or Disease Manifestations. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18030582"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jamda.2017.05.018","article-title":"Intestinal Permeability Biomarker Zonulin is Elevated in Healthy Aging","volume":"18","author":"Qi","year":"2017","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.7754\/Clin.Lab.2016.160512","article-title":"Plasma Zonulin and its Association with Kidney Function, Severity of Heart Failure, and Metabolic Inflammation","volume":"62","author":"Dschietzig","year":"2016","journal-title":"Clin. Lab."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11255-017-1741-5","article-title":"Zonulin, inflammation and iron status in patients with early stages of chronic kidney disease","volume":"50","author":"Lukaszyk","year":"2018","journal-title":"Int. Urol. Nephrol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/11\/1828\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:31:18Z","timestamp":1760189478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/11\/1828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,1]]},"references-count":62,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11]]}},"alternative-id":["jcm8111828"],"URL":"https:\/\/doi.org\/10.3390\/jcm8111828","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,1]]}}}